George Kumar Highlighted Study on Fc-Optimized CD40 Agonist in Cancer Cell
George Kumar, Senior Director at AstraZeneca, shared a post on LinkedIn about a recent article by Juan C. Osorio et al., published in Cancer Cell:
“Fc-optimized CD40 Agonistic Antibody Elicits Tertiary Lymphoid Structure Formation and Systemic Antitumor Immunity in Metastatic Cancer, Cancer Cell (2025)
In the first-in-human Phase I trial (NCT04059588), now reported in Cancer Cell, 12 patients received the Fc-optimized CD40 agonist 2141.V11. Tumor shrinkage occurred in six patients, with two achieving complete responses—one with melanoma and one with breast cancer. Importantly, the therapeutic effect extended beyond the injected lesions: uninjected tumors in distant sites also regressed or were eliminated by immune cells.
‘This effect—where you inject locally but see a systemic response—is rarely observed in clinical treatment. It represents another dramatic and unexpected outcome from our study.’ notes Jeffrey V. Ravetch– senior author from the Laboratory of Molecular Genetics and Immunology, Rockefeller University, New York, NY 10065, USA.
Figure Courtesy: Cancer Cell”
Title: Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer
Journal: Cell Press
Authors: Juan C. Osorio, David A. Knorr, Polina Weitzenfeld, Lucas Blanchard, Ning Yao, Maria Baez, Carlo Sevilla, Meghan DiLillo, Jahan Rahman, Ved P. Sharma, Jacqueline Bromberg, Michael A. Postow, Charlotte Ariyan, Mark E. Robson, Jeffrey V. Ravetch
More posts featuring George Kumar on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023